Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease

Chinese Journal of Integrative Medicine

Volumn 18, Issue 2, 2012, Pages 152-160

  Dong, Hui ^a   Lu, Fu Er ^a   Zhao, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chinese herbal medicine; Nonalcoholic fatty liver disease

Indexed keywords

ARTEMISIA SACRORUM EXTRACT; BERBERINE; BIFENDATE; DANNING TABLET; EMODIN; HERBACEOUS AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; POLYGONUM HYPOLEUCUM EXTRACT; PUERARIN; QUSHI HUAYU DECOCTION; RESVERATROL; SCHIZANDRIN B; SINI POWDER; SIRTUIN 1; THEAFLAVIN; UNCLASSIFIED DRUG; YINCHENHAO DECOCTION;

ALISMA ORIENTALIS; ARTEMISIA; ARTEMISIA SACRORUM; CHINESE HERB; CHINESE MEDICINE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FERMENTUM RUBRUM; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; LIPID STORAGE; MEDICINAL PLANT; NONALCOHOLIC FATTY LIVER; NONHUMAN; POLYGONUM; POLYGONUM HYPOLEUCUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHISANDRAE FRUCTUS; UPREGULATION;

ANIMALS; DRUGS, CHINESE HERBAL; FATTY LIVER; HUMANS; PLANT EXTRACTS;

EID: 84862726594     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-0993-2     Document Type: Review

References (64)

1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009;50:204-210.
2. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-889.
3. Williams R. Global challenges in liver disease. Hepatology 2006;44:521-526. (Pubitemid 44433707)
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
5. Sheth SG, Gordon FD, Chopra S. Nonalcohol ic steatohepatitis. Ann Intern Med 1997;126:137-145. (Pubitemid 27058588)
6. Wang YX, Wang LT, Gao YQ, Sun XH, Zhang B, He JY, et al. Epidemic survey on TCM syndrome typing and preliminary discussion on TCM etiology and pathogenesis of fatty liver. Chin J Integr Tradit West Med (Chin) 2005;25:126-130.
7. Wang LT. Thinking on integrative medicine for treatment of non-alcoholic fatty liver disease. Chin J Integr Tradit West Med (Chin) 2009;29:1061-1063.
8. Tang DC. Herbology. Shanghai: Shanghai University of Traditional Chinese Medicine Press; 2006:74.
9. Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004;25:496-502.
10. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40:S17-S29. (Pubitemid 44309539)
11. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8:774-785. (Pubitemid 47462132)
12. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 2009;296:E812-E819.
13. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 2008;31:1169-1176. (Pubitemid 351871171)
14. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, et al. Berberine reduces the methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 2010;51:2504-2515.
15. Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism 2011;60:298-305.
16. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 2009;296:E955-E964.
17. Hsiang CY, Wu SL, Cheng SE, Ho TY. Acetaldehydeinduced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factorkappaB signaling pathway in HepG2 cells. J Biomed Sci 2005;12:791-801.
18. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006;47:1281-1288. (Pubitemid 43830720)
19. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-1351. (Pubitemid 40022716)
20. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signalregulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005;25:2170-2176. (Pubitemid 41416317)
21. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008;294:E148-E156.
22. Lee S, Lim HJ, Park HY, Lee KS, Park JH, Jang Y. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis 2006;186:29-37.
23. Liang KW, Ting CT, Yin SC, Chen YT, Lin SJ, Liao JK, et al. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol 2006;71:806-817. (Pubitemid 43208837)
24. Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 2007;362:853-857. (Pubitemid 47390652)
25. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008;57:1029-1037. (Pubitemid 351978060)
26. Fan E, Jiang S, Zhang L, Bai Y. Molecular mechanism of apoptosis induction by resveratrol, a natural cancer chemopreventive agent. Int J Vitam Nutr Res 2008;78:3-8.
27. Jiang WJ. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 2008;373:341-344.
28. Tian WX. Inhibition of fatty acid synthase by polyphenols. Curr Med Chem 2006;13:967-977.
29. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008;29:698-706. (Pubitemid 351799479)
30. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009;77:1053-1063.
31. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010;59:554-563.
32. Aoun M, Michel F, Fouret G, Casas F, Jullien M, Wrutniak-Cabello C , et al. A polyphenol extract modifies quantity but not quality of liver fatty acid content in high-fat-high-sucrose diet-fed rats: possible implication of the sirtuin pathway. Br J Nutr 2010;104:1760-1770.
33. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9:327-338.
34. Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, Zhou XH. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 2009;380:644-649.
35. Fullerton MD, Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010;59:551-553.
36. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008;283:20015-20026.
37. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, García-Urkia N, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008;9;8:40.
38. Dong H, Lu FE, Gao ZQ, Xu LJ, Wang KF, Zou X. Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw. World J Gastroenterol 2005;11:1339-1344. (Pubitemid 40425917)
39. Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res 2007;48:2334-2343.
40. Pan SY, Dong H, Zhao XY, Xiang CJ, Fang HY, Fong WF, et al. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol 2008;60:399-403. (Pubitemid 351269829)
41. Pan SY, Yang R, Dong H, Yu ZL, Ko KM. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol 2006;552:170-175. (Pubitemid 44648081)
42. Zheng P, Ji G, Ma Z, Liu T, Xin L, Wu H, et al. Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 2009;37:69-83.
43. Kuo YC, Sun CM, Ou JC, Tsai WJ. A tumor cell growth inhibitor from Polygonum hypoleucum Ohwi. Life Sci 1997;61:2335-2344.
44. Chen CH, Chang MY, Lin YS, Lin DG, Chen SW, Chao PM. A herbal extract with acetyl-coenzyme A carboxylase inhibitory activity and its potential for treating metabolic syndrome. Metabolism 2009;58:1297-1305.
45. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, Shaikenov TE, et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA 2006;103:8552-8557. (Pubitemid 43838493)
46. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116:817-824. (Pubitemid 43326891)
47. Chao PM, Kuo YH, Lin YS, Chen CH, Chen SW, Kuo YH. The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress. J Agric Food Chem 2010;58:5174-5180.
48. Yuan HD, Yuan HY, Chung SH, Jin GZ, Piao GC. An active part of Artemisia sacrorum Ledeb. attenuates hepatic lipid accumulation through activating AMP-activated protein kinase in human HepG2 cells. Biosci Biotechnol Biochem 2010;74:322-328.
49. Gu X, Xie Z, Wang Q, Liu G, Qu Y, Zhang L, et al. Transcriptome profiling analysis reveals multiple modulatory effects of Ginkgo biloba extract in the liver of rats on a highfat diet. FEBS J 2009;276:1450-1458.
50. Pan SY, Yu ZL, Dong H, Xiang CJ, Fong WF, Ko KM. Ethanol extract of Fructus Schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity. Evid Based Complement Alternat Med 2009 Jul 10. [Epub ahead of print].
51. Yan MX, Chen ZY, He BH. Effect of total flavonoids of Chinese hawthorn leaf on expression of NF-κB and its inhibitor in rat liver with non-alcoholic steato-hepatitis. China J Tradit Chin Med Pharm (Chin) 2009;24:139-143.
52. Hong X, Tang H, Wu L, Li L. Protective effects of the Alisma orientalis extract on the xperimental nonalcoholic fatty liver disease. J Pharm Pharmacol 2006;58:1391-1398. (Pubitemid 44580570)
53. Fan XF, Deng YQ, Ye L, Li YD, Chen J, Lu WW, et al. Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med 2010;16:119-123.
54. Lee TY, Chang HH, Lo WC, Lin HC. Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis. Int J Mol Med 2010;25:837-844.
55. Li HS, Feng Q, Hu YY. Effect of Qushi Huayu Decoction on high-fat diet induced hepatic lipid deposition in rats. Chin J Integr Tradit West Med (Chin) 2009;29:1092-1095.
56. Zhang H, Feng Q, Li HS, Chen SD, Wang XN, Peng JH, et al. Effects of Qushi Huayu Decoction on cathepsin B and tumor necrosis factor-alpha expression in rats with non-alcoholic steatohepatitis. J Chin Integr Med (Chin) 2008;6:928-933.
57. Li HS, Feng Q, Xu LL, Chen SD, Li XM, Hu YY. Effects of Qushi Huayu Decoction in prevention and treatment of fatty liver in rats based on adiponection-free fatty acid pathway. J Chin Integr Med (Chin) 2009;7:546-551.
58. Zhang H, Hu YY, Feng Q. Inhibitory effects of Qushi Huayu Decoction on fatty deposition and tumor necrosis factor alpha secretion in HepG2 cells induced by free fatty acid. Chin J Integr Tradit West Med (Chin) 2007;27:1105-1109.
59. Fan JG. Evaluating the efficacy and safety of Danning Tablets in the short-term treatment of patients with nonalcoholic fatty liver disease: a multicenter clinical trial. Hepatobiliary Pancreat Dis Int 2004;3:375-380.
60. Ji G, Fan JG, Chen JJ, Lu LG, Xing LJ, Zheng PY, et al. Effectiveness of Danning Tablet in patients with nonalcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. J Chin Integr Med (Chin) 2008;6:128-133. (Pubitemid 351255890)
61. Zhang Q, Zhao Y, Zhang DB, Sun LJ. Ef fect of Sinai san Decoction on the development of nonalcoholic steatohepatitis in rats. World J Gastroenterol 2005;11:1392-1395. (Pubitemid 40425928)
62. Wang N, Dong H, Wei SC, Lu FE. Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty Liver disease. J Huazhong Univ Sci Technol Med Sci (Chin) 2008;28:295-298.
63. Ma Y, Zhao J, Yang S, Jia Y. Cigu Xiaozhi Pills's influence on lipid peroxidation and TNF-alpha expression in liver tissues of rats with nonalcoholic steatohepatitis. China J Chin Mater Med (Chin) 2010;35:1292-1297.
64. Wang T, Zhang DQ, Li YH, Liu H, Liu ZB, Zhao CF, et al. Regulation effects on abnormal glucose and lipid metabolism of TZQ-F, a new kind of Traditional Chinese Medicine. J Ethnopharmacol 2010;128:575-582.